Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CA6 | P23280 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | KMO | O15229 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | UNG | P13051 | 1/20 | 0.48 |
| ▸ | DAO | P14920 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | RXRA | P19793 | 1/20 | 0.44 |
| ▸ | RXRB | P28702 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4973133 | 0.84 | CA12 (0.56) | CA12CA1CA2CA6CA9 | |
| SCHEMBL1044594 | 0.83 | ATM (0.65) | CA1CA2HPGDHSD17B10KMT2A | |
| SCHEMBL5664511 | 0.83 | GSK3B (0.42) | CA12CA1CA2CA6CA9 | |
| SCHEMBL10412856 | 0.81 | CA12 (0.52) | CA12CA1CA2CA6CA9 | |
| SCHEMBL1927619 | 0.81 | SLC7A11 (0.55) | CA12CA1CA2CA6CA9 | |
| SCHEMBL16956307 | 0.81 | CA12 (0.52) | CA12CA1CA2CA6CA9 | |
| SCHEMBL103415 | 0.81 | ALDH1A1 (0.47) | CA12CA1CA2CA6CA9 | |
| SCHEMBL7136929 | 0.81 | PARP1 (0.55) | HSD17B10TSHRKMT2A | |
| SCHEMBL5389398 | 0.81 | MEN1 (0.50) | HPGDHSD17B10TP53KMT2ANPC1 | |
| SCHEMBL29441888 | 0.81 | GSK3B (0.62) | CA12CA1CA2CA6CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 436 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106103463-B | Bridging type nucleosides and nucleotide | 国立大学法人大阪大学 | 2018-11-30 | — | — | CN | claimed |
| US-10087178-B2 | Substituted spiropyrido[1,2-a]pyrazine derivative and medicinal use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. (JP) | 2018-10-02 | — | — | US | claimed |
| EP-3109254-B1 | CROSSLINKED NUCLEOSIDE AND NUCLEOTIDE | UNIV OSAKA (JP) | 2018-04-11 | — | — | EP | claimed |
| EP-2940019-B1 | SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND MEDICINAL USE THEREOF AS HIV INTEGRASE INHIBITOR | JAPAN TOBACCO INC (JP) | 2018-03-28 | — | — | EP | claimed |
| US-20170044156-A1 | SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND MEDICINAL USE THEREOF AS HIV INTEGRASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2017-02-16 | — | — | US | claimed |
| EP-2940019-A1 | SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND MEDICINAL USE THEREOF AS HIV INTEGRASE INHIBITOR | Japan Tobacco, Inc. (JP) | 2015-11-04 | — | — | EP | claimed |
| CN-104903323-A | Substituted spiropyrido [1,2-a ] pyrazine derivative and medical application thereof as HIV integrase inhibitor | JAPAN TOBACCO INC | 2015-09-09 | — | — | CN | claimed |
| EP-2632576-B1 | METHOD FOR MAKING A COMPOSITE POLYAMIDE MEMBRANE | DOW GLOBAL TECHNOLOGIES LLC (US) | 2014-10-08 | — | — | EP | claimed |
| US-20140221378-A1 | SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND PHARMACEUTICAL USE OF SAME AS HIV INTEGRASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2014-08-07 | — | — | US | claimed |
| US-20100240613-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2010-09-23 | — | — | US | claimed |
| US-20080312228-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2008-12-18 | — | — | US | claimed |
| EP-0254627-B1 | DERIVATIVES OF BENZHYDRYLOXYETHYLPIPERAZINE, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Société anonyme: LES LABORATOIRES MERAM (FR) | 1992-06-17 | — | — | EP | claimed |
| CN-87104734-A | Benzhydryloxyethylpiperazine derivatives, process for their preparation and pharmaceutical compositions containing them | — | 1988-04-06 | — | — | CN | claimed |
| EP-0254627-A1 | Derivatives of benzhydryloxyethylpiperazine, processes for their preparation and pharmaceutical compositions containing them | Société anonyme: LES LABORATOIRES MERAM (FR) | 1988-01-27 | — | — | EP | claimed |
| WO-2024135721-A1 | METHOD FOR PRODUCING PRODUCTION INTERMEDIATE, PRODUCTION INTERMEDIATE THEREOF, AND METHOD FOR PRODUCING CROSSLINKED ARTIFICIAL NUCLEIC ACID INTERMEDIATE BY USING SAME | 田辺三菱製薬株式会社 | 2024-06-27 | — | — | WO | disclosed |
| WO-2024101446-A1 | MODIFIED NUCLEOSIDE HAVING GUANIDINO STRUCTURE IN BRIDGED PART AND METHOD FOR PRODUCING OLIGONUCLEOTIDE USING SAME | ルクサナバイオテク株式会社 | 2024-05-16 | — | — | WO | disclosed |
| CN-112513062-B | Oligonucleotide-containing small cell lung cancer therapeutic agent | 国立大学法人大阪大学 | 2024-05-10 | — | — | CN | disclosed |
| EP-0254627-A1 | Derivatives of benzhydryloxyethylpiperazine, processes for their preparation and pharmaceutical compositions containing them | Société anonyme: LES LABORATOIRES MERAM (FR) | 1988-01-27 | — | — | EP | disclosed |
| EP-0180897-A2 | 5-Fluorouracil derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-05-14 | — | — | EP | disclosed |
| EP-0180188-A2 | A composition for increasing the anti-cancer activity of an anti-cancer compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10087178-B2 | Substituted spiropyrido[1,2-a]pyrazine derivative and medicinal use thereof as HIV integrase inhibitor | IMPDH1, IMPDH2, SAV1 | CA12 4740/4885CA1 4828/4885CA2 3458/4885 |
| US-20100240613-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | TYMP, TYMS, DPYD | CA12 2790/4885CA1 2747/4885CA2 1962/4885 |
| US-20140221378-A1 | SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND PHARMACEUTICAL USE OF SAME AS HIV INTEGRASE INHIBITOR | IMPDH1, IMPDH2, IMPA1 | CA12 4782/4885CA1 4847/4885CA2 3181/4885 |
| US-20080312228-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | TYMP, TYMS, DPYD | CA12 2790/4885CA1 2747/4885CA2 1962/4885 |
| US-20170044156-A1 | SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND MEDICINAL USE THEREOF AS HIV INTEGRASE INHIBITOR | IMPDH1, IMPDH2, SAV1 | CA12 4740/4885CA1 4828/4885CA2 3458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.